Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602602 | 1.00 | SPHK2 (0.58) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL5267939 | 1.00 | SPHK2 (0.58) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL1190565 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL80752 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL3605585 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL7561453 | 0.95 | SPHK2 (0.53) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL6252758 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4186350 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4186357 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL10749955 | 0.90 | PREP (0.67) | SPHK2PREPCTRB1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312471-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-12390536-B2 | Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound | ASTELLAS PHARMA INC. (JP) | 2025-08-19 | — | — | US | disclosed |
| EP-4587446-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| EP-4566633-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | Astellas Pharma, Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| US-20250025567-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-01-23 | — | — | US | disclosed |
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-0510333-A1 | Substituted oxotremorine derivatives | AMERICAN CYANAMID COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0309624-B1 | COMPOSITION FOR ENHANCING PERCUTANEOUS ADMINISTRATION OF MEDICINE | NITTO DENKO CORPORATION (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0467856-A2 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-5059628-A | Proline or prolinol ester to enhance absorption | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-10-22 | — | — | US | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0309624-A1 | Composition for enhancing percutaneous administration of medicine | NITTO DENKO CORPORATION (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4596819-A | Antidepressive agents | WARNER-LAMBERT COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390536-B2 | Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound | TLR6, TLR5, TLR7 | SPHK2 3182/4885PREP 2585/4885ACE2 2854/4885 |
| US-20250312471-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | TLR7, TLR1, TLR2 | SPHK2 2351/4885PREP 4561/4885ACE2 3344/4885 |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | SPHK2 1591/4885PREP 901/4885ACE2 732/4885 |
| US-20250025567-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | TLR6, TLR5, TLR7 | SPHK2 3182/4885PREP 2585/4885ACE2 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.